|1.||Newman-Tancredi, Adrian: 3 articles (09/2008 - 08/2005)|
|2.||Depoortere, Ronan: 2 articles (01/2011 - 11/2003)|
|3.||Boulay, Denis: 2 articles (01/2011 - 11/2003)|
|4.||Bardin, Laurent: 2 articles (09/2008 - 09/2006)|
|5.||Barret-Grévoz, Catherine: 2 articles (09/2006 - 08/2005)|
|6.||Kleven, Mark S: 2 articles (09/2006 - 08/2005)|
|7.||Perrault, G: 2 articles (08/2005 - 06/2004)|
|8.||Griebel, G: 2 articles (08/2005 - 06/2004)|
|9.||Scatton, Bernard: 2 articles (12/2003 - 11/2003)|
|10.||Françon, Dominique: 2 articles (12/2003 - 11/2003)|
|1.||Schizophrenia (Dementia Praecox)
12/01/2003 - "This study shows that the combination of D(2) receptor antagonism and 5-HT(1A) agonism, in the same dose range, confers on SSR181507 a unique neurochemical and electrophysiological profile and suggests the potential of this compound for the treatment of the main dimensions of schizophrenia."
08/01/2005 - "Collectively, these results suggest that SSR181507 can alleviate disturbances of novelty discrimination in a social context in rats, and that this paradigm may represent a suitable animal model of selective attention deficits observed in schizophrenia."
11/01/2003 - "The pharmacological profile of SSR181507 suggests that it should control the symptoms of schizophrenia, in the absence of extrapyramidal signs and cognitive deficits, with the additional benefit of antidepressant/anxiolytic activities."
06/01/2004 - "These data suggest that, in addition to its atypical antipsychotic profile and antidepressant/anxiolytic activities, SSR181507 has a potential therapeutic activity in another key feature of schizophrenia poorly controlled by current antipsychotics, namely deterioration in social functioning."
01/01/2011 - "SSR181507, a dopamine D₂ receptor antagonist/partial agonist and 5-HT(₁A) receptor agonist, is active in animal models of schizophrenia. "
08/01/2005 - "In contrast, SSR181507 and bifeprunox potently inhibited both CLP and bar catalepsy. "
08/01/2005 - "In contrast, only modest catalepsy was induced by aripiprazole and SSR181507, even following a higher dose of WAY100635 (2.5 mg/kg). "
11/01/2003 - "Coadministration of the selective 5-HT(1A) blocker SL88.0338 produced catalepsy and antagonized the effects of SSR181507 in the depression/anxiety tests, confirming the view that activation of 5-HT(1A) receptors confers an atypical profile on SSR181507, and is responsible for its antidepressant/anxiolytic properties. "
11/01/2003 - "SSR181507 did not induce catalepsy in rats (MED>60 mg/kg i.p.) and antagonized (3-10 mg/kg i.p.) haloperidol-induced catalepsy. "
09/01/2006 - "When 5-HT1A receptors were blocked by pretreatment with WAY100635 (2.5 mg/kg, s.c.), cataleptogenic properties of SSR181507 and sarizotan were unmasked, and the catalepsy induced by bifeprunox was enhanced. "
09/11/2008 - "A variety of mechanisms likely underlie the hyperglycemia and corticosterone release observed with clozapine and olanzapine, whilst the balance of dopamine D2/3/5-HT1A interaction may contribute to the less favourable impact of SLV313 and SSR181507 compared with that of bifeprunox and F15063."
|1.||Antipsychotic Agents (Antipsychotics)
|3.||1- (2,3- dihydro- 1,4- benzodioxin- 5- yl)- 4- ((5- (4- fluorophenyl)- 3- pyridinyl)methyl)piperazine
|9.||Risperidone (Risperdal Consta)